CTOs on the Move


 
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.erasca.com
  • 10835 Road to the Cure Suite 140
    San Diego, CA USA 92121
  • Phone: 858.465.6511

Executives

Name Title Contact Details

Funding

Erasca raised $42M on 12/18/2018
Erasca raised $22M on 03/05/2019
Erasca raised $200M on 04/27/2020
Erasca raised $36M on 08/31/2020

Similar Companies

DermTech

Welcome to the new era of skin cancer detection. At DermTech we bring precision to the practice of dermatology through non-invasive genomic testing. And we developed the Smart Sticker that`s making it possible. The DermTech Smart Sticker collects an RNA sample by painlessly lifting skin cells off the entire surface of a mole. This gives doctors the power to diagnose skin cancer in its earliest stages—without a scalpel, without cutting, without scarring. After collection, stickers are sent to our team of scientists in the Gene Lab, the only commercial lab to extract nucleic acids and other proteins from non-invasive skin samples. We amplify RNA molecules to detect two specific genes that are highly predictive of melanoma—PRAME and LINC00518. This process provides 10,000x greater precision in the ability to detect melanoma. We have created the step before the scalpel—a tool doctors have never had before. Now the doctor has the choice of using a non-invasive, highly accurate test to check for melanoma without cutting. And this is just the beginning. We are developing other tests using the Smart Sticker that will further advance early disease detection.

Eidos Therapeutics

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.

Dendritic NanoTechnologies

Dendritic NanoTechnologies, Inc. is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carol Cole Company

Carol Cole Company is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scrippshealth

Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.